Novartis wants Japan to link drug price to patient outcomes

to The Nikkei in a recent interview. Japan has never implemented such a payment scheme. At issue is Kymriah, a new treatment for acute lymphoblastic leukemia in children and young adults. Kymriah in August became the first CAR-T cell therapy — one that …
( read original story …)


Related Post

CORRECTED-Nikkei extends 2-year highs on upbeat gl...
views 95
TOKYO, Oct 4 (Reuters) - Japan’s Nikkei share aver...
Bird flu outbreak hits zoo events linked to Year o...
views 123
TOKYO - The recent outbreak of a highly virulent s...
Mizuho Seeks to Challenge Nomura as Japan’s Top Eq...
views 142
Mizuho Financial Group Inc., the Japanese bank tha...
Nikkei edges lower as construction stocks extend s...
views 66
TOKYO, Dec 19 (Reuters) - Japan’s Nikkei share ave...
Osaka’s ¥1 sales energize shoppers but not good fo...
views 158
Osaka is famed for it’s cheap prices, with ¥1 supe...
Bank of Japan Chief: Unwinding Stimulus Won’t Brin...
views 140
TOKYO—Bank of Japan Gov. Haruhiko Kuroda said the ...
Japan economy: Exports help faster-than-expected g...
views 151
But since the election result, the yen has fallen ...
Western Digital offers to exit Toshiba chip bid fo...
views 88
TOKYO (Reuters) - Western Digital Corp (WDC.O) has...
Tokyo RPG Factory’s Lost Sphear Launching Ja...
views 87
Last month at the E3 in Los Angeles, Tokyo RPG Fac...
Japan to acquire air-launched missiles able to str...
views 65
"We are planning to introduce the JSM (Joint Strik...